Ionis Pharmaceuticals, Inc. is fully buying out its cardiovascular-focused subsidiary Akcea Therapeutics, Inc. just as the affiliate's pipeline matures into late-stage development. Ionis announced on 31 August that it will buy the roughly 24% of Akcea it doesn't already own for $18.15 per share, or approximately $500m.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?